Author

S. J. Ho Sui

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. C. Mullen· 1 shared A. Kournoutis· 1 shared A. Onorati· 1 shared C. Bretz· 1 shared C. Sun· 1 shared D. Wrobel· 1 shared J. F. Doerner· 1 shared J. F. Rippmann· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. C. Mullen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologybioRxivOct 4, 2022

Nuclear autophagy interactome unveils WSTF as a constitutive nuclear inhibitor of inflammation

Y. Wang, V. V. Eapen, A. Kournoutis…·Z. Dou

The paper identifies WSTF as a nuclear inhibitor of inflammation degraded by autophagy, showing its role in inflammation, cancer, and immune surveillance.

DOI 10.1038/s41586-025-09234-1

humanmouse

𝕏 PostBluesky

Cell BiologybioRxivOct 8, 2021

Nanchangmycin regulates FYN, FAK and ERK to control the fibrotic activity of hepatic stellate cells

W. Li, J. Y. Chen, C. Sun…·A. C. Mullen

This study identifies nanchangmycin as an anti-fibrotic agent that inhibits HSC myofibroblast activity by modulating FYN, FAK, and ERK signaling pathways.

DOI 10.7554/elife.74513

humanexperimental assay

𝕏 PostBluesky